Gastritis

Baicalein, an active flavone from Scutellaria baicalensis (Baikal skullcap), inhibited production of IL-6, IL-8, and MCP-1 in IL-1β- and TNF-α-activated human mast cells (HMC-1 line) dose-dependently via NF-κB pathway suppression, as published in PMC2206049 (Clinical and Molecular Allergy, 2007). It also inhibits 5-lipoxygenase, reducing leukotriene synthesis from mast cells.

Baicalin, the glucuronide of baicalein found in Baikal skullcap (Scutellaria baicalensis), inhibits 5-lipoxygenase and NF-κB, reducing leukotriene and cytokine production relevant to mast cell activation. It is the primary circulating form after oral baicalein ingestion and shares its parent compound's mast cell-relevant anti-inflammatory and antihistamine mechanisms, used in traditional Chinese medicine for allergic conditions.

Nigella sativa (black seed) extract inhibited mast cell degranulation in multiple animal studies, reducing histamine release, intestinal mast cell numbers, and plasma mast cell protease-1 (MMCP-1) in OVA-allergic mice (PMC3387213). Its active compound thymoquinone mediates anti-mast cell effects via NF-κB and 5-LOX inhibition. Traditional use in Islamic and Unani medicine includes allergy, asthma, and allergic rhinitis.

Boswellia serrata resin extract demonstrated dose-dependent mast cell stabilizing activity in compound 48/80-induced degranulation models in rats (PubMed 15320503). Its boswellic acids inhibit 5-LOX, suppress NF-κB, inhibit histamine release, and human mast cell pharmacological studies report up to 71% inhibition of histamine release. Boswellia is used in Ayurvedic medicine for allergy and asthma.

Boswellic acids from Boswellia serrata resin inhibit mast cell degranulation and histamine release via 5-lipoxygenase blockade and NF-κB suppression. A peer-reviewed pharmacological study (PubMed 15320503) using compound 48/80-induced degranulation demonstrated dose-dependent mast cell stabilizing activity at 20–80 mg/kg oral dosing in rats. Human mast cell pharmacological studies reported inhibition of histamine release by up to 71%.

Bromelain, proteolytic enzymes from pineapple stem, reduces mast cell-associated microclotting, modulates Th1/Th2 immune balance, and reduces eosinophil and mast cell tissue infiltration in allergic airway models. It is frequently combined with quercetin in MCAS protocols, where it also enhances quercetin bioavailability. Evidence supports its role in multi-modal mast cell and inflammatory cascade management.

Curcumin inhibits mast cell degranulation by blocking Syk kinase, a pivotal enzyme in IgE-receptor signaling, reducing histamine, TNF-α, and IL-4 release. Murine allergy models confirm suppression of allergic responses and IgE-mediated mast cell activation. It is widely cited as a natural mast cell stabilizer in MCAS management protocols, though poor bioavailability requires enhanced delivery forms.

Diamine oxidase (DAO) is the primary enzyme responsible for degrading histamine in the GI tract. DAO deficiency is directly implicated in histamine accumulation central to MCAS and histamine intolerance. DAO enzyme supplements (primarily from porcine kidney extract) taken before meals have been studied in clinical trials for histamine-intolerance symptom reduction, and are specifically listed by the Mast Cell Action charity as relevant for MCAS management.

EGCG, the major catechin in green tea, inhibits mast cell histamine release by blocking tyrosine phosphorylation of focal adhesion kinase pp125(FAK) and suppressing intracellular Ca2+ influx, as documented in PubMed (PMID 10924324). Both in vitro (RBL-2H3, rat peritoneal mast cells) and in vivo animal studies confirm dose-dependent suppression of degranulation and histamine. EGCG also inhibits histidine decarboxylase, reducing histamine biosynthesis.

Fisetin, a flavonol in strawberries and other fruits, inhibited IgE-mediated and PMACI-stimulated histamine release in RBL-2H3 mast cells in a peer-reviewed Archives of Pharmacal Research study. It suppressed intracellular Ca2+ elevation and gene expression/production of TNF-α, IL-1β, IL-6, and IL-8, while blocking NF-κB nuclear translocation and DNA binding.

Kaempferol inhibits IgE-induced mast cell degranulation and cytokine production in bone marrow-derived mast cells (BMMCs) by downregulating surface FcεRI expression and upregulating the inhibitory phosphatase SHIP1, as documented in PMC10059252 (2023). It also inhibits LPS- and IL-33-induced IL-6 production, acting as a multi-stimulus mast cell modulator.

Luteolin, a flavone in celery, chamomile, and green peppers, is among the most potent natural mast cell stabilizers studied in human mast cell models, outperforming pharmaceutical cromolyn for histamine and cytokine suppression in some in vitro assays. It inhibits histamine, leukotriene, and prostaglandin D2 release concentration-dependently via Ca2+ and PKC blockade. It uniquely crosses the blood-brain barrier, making it relevant for neuroinflammatory MCAS presentations.

Magnesium is a required cofactor for diamine oxidase (DAO) enzyme activity, which degrades histamine central to MCAS. Deficiency is associated with increased mast cell reactivity and amplified histamine-related symptoms. Integrative MCAS practitioners report near-universal deficiency in their patient populations and list magnesium among the most critical nutrients for MCAS management.

Myricetin, a flavonol in berries, red wine, and tea, inhibited IgE- and PMACI-mediated histamine release and intracellular calcium elevation in RBL-2H3 mast cells in a peer-reviewed comparative study. It suppressed TNF-α and IL-6 production and blocked NF-κB activation. It is described in primary literature as a particularly effective mast cell stabilizer.

Nettle leaf (Urtica dioica) inhibits H1 histamine receptors, stabilizes mast cell membranes to reduce degranulation, inhibits mast cell tryptase, and blocks COX-1/COX-2 prostaglandin synthesis. It is specifically cited in MCAS management protocols as a natural antihistamine and mast cell stabilizer, and has been studied in a double-blind trial for allergic rhinitis.

Omega-3 fatty acids (EPA and DHA) reduce systemic inflammation by shifting eicosanoid production toward less inflammatory prostaglandin and leukotriene series, reducing the intensity of mast cell-derived inflammatory cascades. The Mast Cell Action charity specifically lists omega-3s for anti-inflammatory support in MCAS, particularly when a low-histamine diet restricts omega-3-rich fish. They also support gut barrier integrity relevant to mast cell hyperactivation.

Pyridoxal-5-Phosphate (P-5-P) is the biologically active coenzyme form of vitamin B6, serving as a direct cofactor for diamine oxidase (DAO) activity required for histamine catabolism in MCAS. Preferred over standard pyridoxine in patients with impaired B6 phosphorylation, P-5-P is included in MCAS micronutrient protocols to support DAO-mediated histamine breakdown and reduce mast cell activation symptom burden.

Palmitoylethanolamide (PEA), an endogenous lipid mediator, directly reduces mast cell degranulation through CB2 receptor-dependent activation and by stimulating 2-arachidonoylglycerol (2-AG) biosynthesis. Multiple peer-reviewed studies in RBL-2H3 cells and in vivo animal models confirm inhibition of substance P-induced histamine release and reduction of mast cell numbers in inflamed tissues. PEA is approved in Europe as a dietary food for special medical purposes for neuropathic and neuro-inflammatory conditions.

Quercetin is one of the most extensively studied natural mast cell stabilizers. In vitro studies in human mast cells show it inhibits histamine release, suppresses tryptase activity, and blocks IgE-dependent degranulation via Ca2+ influx inhibition and NF-κB suppression. It has outperformed the pharmaceutical mast cell stabilizer cromolyn in some cell-based human mast cell assays. Typical supplemental doses studied range from 500–1,000 mg/day.

Resveratrol inhibits FcεRI-mediated mast cell degranulation and cytokine/chemokine expression dose-dependently in mature human intestinal mast cells isolated from surgical tissue, as published in PMC8307672. Mechanisms include blockade of mitochondrial and nuclear ERK1/2 and STAT3 phosphorylation. Animal models confirm prevention of food allergy and atopic dermatitis mediated by mast cell activity.

Rutin, a quercetin glycoside in buckwheat and citrus, inhibited IgE-mediated histamine release and intracellular calcium elevation in RBL-2H3 mast cells, and suppressed TNF-α, IL-1β, IL-6, and IL-8 production while blocking NF-κB in a peer-reviewed comparative study. It is included in the NeuroProtek formulation developed by Tufts mast cell researcher Dr. Theoharis Theoharides for MCAS and neuroinflammatory conditions.

Thymoquinone (TQ), the principal bioactive of Nigella sativa volatile oil (30–48%), inhibits activated mast cell TNF-α transcription via NF-κB blockade, blocks 5-LOX and LTC4-synthase reducing leukotriene formation in human blood, and reduces intestinal mast cell numbers and plasma mast cell protease-1 (MMCP-1) in OVA-allergic mice (PMC3387213). In vitro, TQ prevents mast cell histamine release in allergic disease models.

Vitamin B6 (pyridoxine) is an essential cofactor for diamine oxidase (DAO), the primary histamine-degrading enzyme in the gut, and also supports the HNMT (histamine N-methyltransferase) histamine catabolism pathway. Deficiency impairs DAO activity and increases histamine accumulation in MCAS and histamine intolerance. It is included in MCAS protocols as a standard DAO support micronutrient.

Vitamin C supports MCAS management by promoting endogenous DAO enzyme production (aiding histamine degradation) and participating as a cofactor in histamine catabolism. A clinical study found 2,000 mg/day decreased plasma histamine levels. It is listed by integrative MCAS clinicians as a foundational supplement that also synergizes with quercetin for mast cell membrane stabilization.

Vitamin D, acting via its nuclear vitamin D receptor (VDR) on mast cells, directly suppresses IgE-mediated mast cell activation and inflammatory mediator release. A 2016 peer-reviewed study (PubMed 27998003) concluded vitamin D is required for mast cell stability and that deficiency causes mast cell activation. VDR-dependent calcitriol signaling reduces histamine and leukotriene release from bone marrow-derived and human mast cells.

Vitamin D3 (cholecalciferol) is the preferred supplemental form of vitamin D, with evidence for mast cell stabilization via VDR-dependent suppression of IgE-mediated degranulation. A 2016 PubMed study confirmed VDR signaling is required for mast cell stability, and deficiency causes activation. D3 raises serum 25(OH)D more effectively than D2, making it the clinically recommended form for MCAS-related vitamin D protocols.

Zinc is an essential cofactor for diamine oxidase (DAO) synthesis and activity, the primary histamine-degrading enzyme. Deficiency reduces DAO activity and increases histamine accumulation relevant to MCAS. Zinc also has direct anti-inflammatory effects via NF-κB inhibition and reduction of pro-inflammatory cytokines involved in mast cell-mediated inflammation.